OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. El Chaer on the Potential for Combination Strategies With Ruxolitinib in MPNs

November 25th 2020

Firas El Chaer, MD, discusses the potential utility of combination strategies with ruxolitinib in patients with myeloproliferative neoplasms.

Dr. Kim on Curative Treatment Options in HCC

November 25th 2020

Joseph Kim, MD, discusses curative therapeutic options in hepatocellular carcinoma.

Dr. Brody on Managing CAR T-Cell Therapy Toxicities in MCL

November 25th 2020

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

Dr. Boutros on the Utility of Genetic Testing in Prostate Cancer

November 24th 2020

Paul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.

Dr. Opyrchal on the Current State of Biomarkers in TNBC

November 24th 2020

Mateusz Opyrchal, MD, PhD, discusses the current state of biomarkers in triple-negative breast cancer.

Dr. Mikhael on Remaining Challenges in High-Risk Multiple Myeloma

November 24th 2020

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

Dr. Luke the Role of Molecular Testing in Melanoma

November 24th 2020

Jason J. Luke, MD, FACP, discusses the role of molecular testing in melanoma.

Dr. Janjigian on the Importance of First-Line Therapy Selection in Gastric Cancer

November 24th 2020

Yelena Y. Janjigian, MD, discusses the importance of selecting an optimal first-line therapy in gastric cancer.

Dr. Dorritie on Determining Transplant Eligibility in Multiple Myeloma

November 24th 2020

Kathleen A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

Dr. Lin on the Limitations of Current Biomarkers in Prostate Cancer

November 23rd 2020

Daniel W. Lin, MD, discusses the limitations of currently available biomarkers in prostate cancer.

Dr. Price on the Challenges of the CodeBreaK 100 Trial in GI Cancers

November 23rd 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses challenges faced during the CodeBreaK 100 trial in gastrointestinal cancers.

Dr. Chaft on the Rationale for the OPAL Trial in EGFR+ NSCLC

November 23rd 2020

Jamie E. Chaft, MD, discusses the rationale behind the OPAL trial in EGFR-mutant non–small cell lung cancer.

Dr. Ruan on Treatment Considerations in MCL

November 23rd 2020

Jia Ruan, MD, PhD, discusses treatment considerations in mantle cell lymphoma.

Dr. Eng on Features of High-Risk CRC

November 23rd 2020

Cathy Eng, MD, FACP, FASCO, discusses the features of high-risk colorectal cancer.

Dr. Mascarenhas on Emerging Agents in Myelofibrosis

November 23rd 2020

John O. Mascarenhas, MD, discusses emerging agents in myelofibrosis.

Dr. Chaft on the Next Steps of Osimertinib Research in EGFR+ NSCLC

November 20th 2020

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Dr. Tsuboi on Findings From the Phase 3 ADAURA Trial in EGFR+ NSCLC

November 20th 2020

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in EGFR-mutant non–small cell lung cancer.

Dr. Iwata on Final OS Results From the Phase 3 IMpassion130 Trial in TNBC

November 20th 2020

Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival results from the phase 3 IMpassion130 trial in triple-negative breast cancer.

Dr. Mikhael on Unmet Needs in Triple-Class Refractory Multiple Myeloma

November 19th 2020

Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.

Dr. Trent on the Potential Role of Immunotherapy in GIST

November 19th 2020

Jonathan C. Trent, MD, PhD, discusses the potential role of immunotherapy in gastrointestinal stromal tumors.